Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

The umbrella term is called photobiomodulation therapy, which covers other colors, or wavelengths, that have health benefits.

Explore 2025's tech-infused skincare trends with revolutionary beauty treatments that promise flawless, radiant skin. Get ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

Ageing is a natural and unavoidable phenomenon that brings with it various health challenges, including arthritis, memory loss, joint degeneration, lung fibrosis, and other complications.

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 13.Invest with Confidence: ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $96.49 and traded as low as $93.22.

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year.

Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...